Chronic Inflammatory Demyelinating Polyneuropathy Market

Market Overview:

The 7 major chronic inflammatory demyelinating polyneuropathy markets reached a value of USD 1,817.2 Million in ​2024​. Looking forward, IMARC Group expects the 7MM to reach USD 3,872.6 Million by 2035, exhibiting a growth rate (CAGR) of 7.13% during ​2025-2035​.

The chronic inflammatory demyelinating polyneuropathy market has been comprehensively analyzed in IMARC's new report titled "Chronic Inflammatory Demyelinating Polyneuropathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ​2025-2035​". Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired autoimmune disease of the peripheral nerve system that causes increasing weakening and reduced sensory function in the legs and arms. The ailment is characterized by the body damaging the myelin sheath. These are the fatty coatings of the fibers that insulate and protect the nerves. The symptoms of CIDP may differ from person to person. However, the most prevalent sign is muscle weakness, which worsens over at least eight weeks. Individuals suffering from this illness might also experience loss of muscle mass (atrophy) in affected muscles, tingling, prickliness or numbness in the fingers and toes, difficulties with balance and coordination, loss of mobility, weakening of deep tendon reflexes, neuropathic pain, etc. Diagnosing CIDP commonly involves a comprehensive evaluation of clinical features, along with a physical and neurological exam. The healthcare provider may also utilize magnetic resonance imaging to detect the thickening of nerve roots and plexuses in the affected areas, like the lumbar or brachial plexus.

The escalating cases of autoimmune disorders, in which the body's immune system attacks the myelin sheaths around nerve cells in the peripheral nervous system, are primarily driving the chronic inflammatory demyelinating polyneuropathy market. In addition to this, the inflating utilization of corticosteroids, such as prednisolone and prednisone, which act by altering the immune system's function and suppressing an abnormal autoimmune response, is also creating a positive outlook for the market. Moreover, the widespread adoption of intravenous immunoglobulin (IVIG) on account of its numerous advantages, such as improved disability, reduced relapses, and enhanced muscle strength in patients, is further bolstering the market growth. Apart from this, the rising usage of plasma exchange technique, which can help to remove harmful antibodies from the blood, leading to decreased inflammation and potentially accelerated nerve conduction velocity, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of stem cell transplant, since it works by alleviating damaged immune cells that are attacking the nerves and replacing them with healthy, new immune cells is expected to drive the chronic inflammatory demyelinating polyneuropathy market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the chronic inflammatory demyelinating polyneuropathy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic inflammatory demyelinating polyneuropathy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic inflammatory demyelinating polyneuropathy market in any manner.

Recent Developments:

• In December ​2024​, Argenx SE reported that VYVDURA had been approved by Japan's Ministry of Health, Labour, and Welfare (MHLW) for people suffering from chronic inflammatory demyelinating polyneuropathy. VYVDURA is approved for CIDP as a once weekly 30 to 90 second subcutaneous injection, which can be self-administered at home.
• In January ​2024​, Takeda announced that the United States FDA had approved HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for the treatment of chronic inflammatory demyelinating polyneuropathy as a maintenance therapy to prevent the relapse of neuromuscular disability and impairment in adults.

Drugs:

Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) is a prescription medication used to treat adult patients who have chronic inflammatory demyelinating polyneuropathy. The medicine acts by identifying and inhibiting the neonatal Fc receptor (FcRn), resulting in a decrease in circulating immunoglobulin G (IgG) antibodies, including potentially damaging IgG autoantibodies that may contribute to myelin sheath destruction in CIDP. The hyaluronidase component of the drug improves absorption by enhancing permeability in the subcutaneous tissue where the injection is delivered.

Panzyga is indicated for the treatment of chronic inflammatory demyelinating polyneuropathy in adults. Panzyga is an infusion-ready liquid medication containing IgG, a protein that aids in infection resistance. It is generated from human plasma that has been donated by healthy persons and contains antibodies. The drug may benefit people with CIDP by improving mobility and hand strength.

HYQVIA, developed by Takeda, is a combination of immune globulin and recombinant human hyaluronidase for chronic inflammatory demyelinating polyneuropathy. The immune globulin provides passive immunity, modulating immune responses and reducing autoantibody-mediated nerve damage. Recombinant hyaluronidase enhances immune globulin absorption, allowing subcutaneous administration with sustained immunomodulatory effects. This helps stabilize nerve function, reducing inflammation, demyelination, and disease progression in CIDP patients.

DNTH103, developed by Dianthus Therapeutics, works by selectively inhibiting the active form of the C1s protein, a key component of the classical complement pathway. This effectively blocks the cascade of inflammatory responses that contribute to the pathology of chronic inflammatory demyelinating polyneuropathy while minimizing disruption to the body's immune system by preserving the alternative and lectin pathways critical for infection defense. Essentially, it targets the immunological pathway that is thought to be driving the disease process in CIDP.

Riliprubart, developed by Sanofi, specifically inhibits the activated C1s protein in the conventional complement system. This efficiently suppresses the cascade of inflammatory responses that contribute to demyelination and axonal damage in chronic inflammatory demyelinating polyneuropathy by attacking the complement system directly. Essentially, it stops the immune system from attacking peripheral neurons by inhibiting the activation of the complement cascade.

Time Period of the Study

• Base Year: ​2024​
• Historical Period: ​2019-2024​
• Market Forecast: ​2025-2035​

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the chronic inflammatory demyelinating polyneuropathy market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the chronic inflammatory demyelinating polyneuropathy market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current chronic inflammatory demyelinating polyneuropathy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the chronic inflammatory demyelinating polyneuropathy market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in ​2024​ and how are they expected to perform till 2035?
• What was the country-wise size of the chronic inflammatory demyelinating polyneuropathy market across the seven major markets in ​2024​ and what will it look like in 2035?
• What is the growth rate of the chronic inflammatory demyelinating polyneuropathy market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035​) of chronic inflammatory demyelinating polyneuropathy across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of chronic inflammatory demyelinating polyneuropathy by age across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of chronic inflammatory demyelinating polyneuropathy by gender across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with chronic inflammatory demyelinating polyneuropathy across the seven major markets?
• What is the size of the chronic inflammatory demyelinating polyneuropathy patient pool (​2019-2024​) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of chronic inflammatory demyelinating polyneuropathy?
• What will be the growth rate of patients across the seven major markets?

Chronic Inflammatory Demyelinating Polyneuropathy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for chronic inflammatory demyelinating polyneuropathy drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic inflammatory demyelinating polyneuropathy market?
• What are the key regulatory events related to the chronic inflammatory demyelinating polyneuropathy market?
• What is the structure of clinical trial landscape by status related to the chronic inflammatory demyelinating polyneuropathy market?
• What is the structure of clinical trial landscape by phase related to the chronic inflammatory demyelinating polyneuropathy market?
• What is the structure of clinical trial landscape by route of administration related to the chronic inflammatory demyelinating polyneuropathy market?